TREML2 anticorps (PE)

N° du produit ABIN2663936

Cet anticorps anti-TREML2 Monoclonal Rat conjugué à PE (Clone MIH47) (ABIN2663936) détecte spécifiquement TREML2 dans FACS. L’anticorps est réactif avec des échantillons de Souris.

Aperçu rapide pour TREML2 anticorps (PE) (ABIN2663936)

Antigène: TREML2 (Triggering Receptor Expressed On Myeloid Cells-Like 2 (TREML2))

Reactivité: Souris

Hôte: Rat

Clonalité: Monoclonal

Conjugué: Cet anticorp TREML2 est conjugé à/à la PE

Application: Flow Cytometry (FACS)

Clone: MIH47

Détail du produit anti-TREML2 anticorps (PE)

Purification: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Isotype: IgG2a kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.2 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Protect from prolonged exposure to light. Do not freeze.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur TREML2

Antigène: TREML2 (Triggering Receptor Expressed On Myeloid Cells-Like 2 (TREML2))

Autre désignation: TLT-2

Sujet: Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2, TREML2) is a type I transmembrane protein in TREM family. It consists of a single extracellular Ig-like domain of the V-type, a transmembrane domain, and a short cytoplasmic domain. TLT-2 is expressed on myeloid , B cells , and macrophages. It was also found to express on CD8+ T cells and activated CD4+ T cells. It regulates innate immune response based on its expression profile, costimulates the activation of T cells. Transduction of TLT-2 into T cells resulted in enhanced IL-2 and IFN-gamma production. It was reported that B3-H7 is a receptor of TLT-2. Blockade of the B7-H3/ TLT-2 pathway with monoclonal antibodies against B7-H3 or TLT-2 efficiently inhibited hypersensitivity response. Further studies are needed to confirm the ligand.